Deding A, Tougaard L, Krogh Jensen M, Rodbro P
Acta Med Scand. 1977;202(4):253-5. doi: 10.1111/j.0954-6820.1977.tb16822.x.
To evaluate changes inbone composition during treatment with corticosteroids, the bone mineral content (BMC, measured by photon absorptiometry) and the degree of bone mineralization (measured as the bone phosphorus/hydroxyproline ratio) were determined in 18 patients during prednisone treatment for haematological and connective tissue diseases. The prednisone dose ranged from 12 to 51 mg/day (mean 27). The BMC decreased significantly (mean 2.5%) during the studied 12 weeks of treatment, but the change did not correlate significantly to the prednisone dose. The degree of bone mineralization remained unchanged, indicating equal losses of mineral and of collagen in bone during prednisone treatment. The changes correspond to a rapidly developing oesteoporotic state.
为评估皮质类固醇治疗期间骨成分的变化,对18例因血液系统疾病和结缔组织疾病接受泼尼松治疗的患者,测定了骨矿物质含量(通过光子吸收法测量的BMC)和骨矿化程度(以骨磷/羟脯氨酸比值衡量)。泼尼松剂量为12至51毫克/天(平均27毫克/天)。在为期12周的研究治疗期间,BMC显著下降(平均2.5%),但该变化与泼尼松剂量无显著相关性。骨矿化程度保持不变,表明泼尼松治疗期间骨中矿物质和胶原蛋白的损失相等。这些变化与快速发展的骨质疏松状态相符。